2 Risky, 2 Safe Pharma Plays

The following video is part of our "Motley Fool Conversations" series, in which advisor James Early and senior technology analyst Eric Bleeker discuss topics across the investing world.

In today's edition, James takes a look at the pharma world and keys in on a phrase that should strike fear into any pharma investor's heart: the dreaded "patent cliff." He's particularly weary that AstraZeneca and Eli Lilly, two companies that face looming patent cliffs, might look to ill-conceived deals in coming years. James recommends that pharma investors instead look to both Johnson & Johnson and GlaxoSmithKline.

One of the best reasons to invest in pharma is the solid dividends paid out by the companies. For example, James' recommendation in this video, as well as those in this report: "Secure Your Future With 11 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost! Just click here to discover the winners we've picked.

Eric Bleeker has no positions in the stocks mentioned above. James Early owns shares of Johnson & Johnson. The Motley Fool owns shares of AstraZeneca, GlaxoSmithKline, and Johnson & Johnson. Motley Fool newsletter services recommend GlaxoSmithKline and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1779624, ~/Articles/ArticleHandler.aspx, 10/25/2016 3:28:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,167.15 -55.88 -0.31%
S&P 500 2,142.73 -8.60 -0.40%
NASD 5,279.63 -30.20 -0.57%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 3:13 PM
JNJ $114.01 Up +0.40 +0.35%
Johnson and Johnso… CAPS Rating: ****
AZN $29.78 Down -0.31 -1.01%
AstraZeneca CAPS Rating: ****
GSK $40.35 Down -0.34 -0.82%
GlaxoSmithKline CAPS Rating: ***
LLY $77.71 Up +0.14 +0.17%
Eli Lilly and Co. CAPS Rating: ***